1. Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma
- Author
-
Philippe Moreau, Florent Malard, Steven Le Gouill, Viviane Dubruille, Virginie Roland, Marion Loirat, Benoit Tessoulin, Beatrice Mahe, Martine Pennetier, Cyrille Touzeau, Nicolas Blin, Mohamad Mohty, Aline Clavert, Lucie Planche, and Pierre Peterlin
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Dexamethasone ,Disease-Free Survival ,Drug Administration Schedule ,Overall response rate ,Recurrence ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,In patient ,Prospective cohort study ,Elderly patient ,Lenalidomide ,Multiple myeloma ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Hematology ,medicine.disease ,Thalidomide ,Surgery ,Treatment Outcome ,Disease Progression ,Female ,Multiple Myeloma ,business ,medicine.drug - Abstract
Few data are available on the efficacy of the combination of lenalidomide plus dexamethasone (Len/Dex) in very elderly patients above 75 years of age with relapsed multiple myeloma (MM). We report here a single-center series of 45 consecutive patients aged 75 years or older with relapsed MM treated with this combination. The overall response rate was 62% and the median progression-free survival was 14 months, which compares favorably to that described in the two pivotal prospective studies that formed the basis for the approval of Len/Dex in the relapse setting. Our study confirms that Len/Dex is an effective combination in very elderly patients with relapsed MM.
- Published
- 2012
- Full Text
- View/download PDF